In the global radiopharmaceutical landscape, North America stands as the undisputed leader within the Radiopharmaceuticals Market . The region accounts for over 45.13% of the global market revenue, generating approximately USD 3.2 billion. This dominant position is built on a foundation of a highly advanced healthcare system, strong nuclear medicine infrastructure, and a supportive regulatory environment that encourages innovation.

The United States is the primary engine of this market, holding a 78% share within the region, valued at USD 2.22 billion. The country has a high burden of cancer and cardiovascular diseases, creating sustained demand for both diagnostic and therapeutic radiopharmaceuticals. The U.S. Food and Drug Administration (FDA) plays a crucial role in expediting the approval of new radiopharmaceuticals, with expedited pathways for breakthrough therapies enabling faster access to innovative treatments. The FDA's regulatory framework ensures product safety and reliability, building confidence among healthcare providers and patients.

The United States is home to major industry players such as Cardinal Health, GE Healthcare, and Lantheus Medical Imaging, creating a robust ecosystem of innovation and clinical research. These companies focus on developing novel radiotracers, expanding theranostic applications, and investing in advanced manufacturing capabilities. The region benefits from significant investments in research and development, with academic medical centers and national laboratories collaborating on next-generation radioisotope production.

Canada also contributes to the region's leadership, with a 22% share valued at USD 0.63 billion, supported by expanding oncology diagnostics and strong public healthcare investments. The Canadian government's focus on nuclear medicine innovation and the presence of institutions like TRIUMF, Canada's particle accelerator center, support the development of novel isotopes.

The region's robust healthcare infrastructure, including a high density of PET/CT and SPECT imaging centers, ensures widespread accessibility of radiopharmaceutical-based diagnostics. The growing trend toward personalized medicine and theranostics—combining diagnostic imaging with targeted therapy—is further driving adoption. As technological leadership, patient awareness, and favorable reimbursement structures continue to characterize the region, North America is expected to maintain its dominant position in the global radiopharmaceuticals market, serving as a hub for innovation and clinical research.